Results 211 to 220 of about 58,791 (313)

Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐CD19 CAR‐T Cells

Cancer Science, EarlyView.
Under normal conditions, CXCL12 stimulation induces CXCR4 degradation. In contrast, CAR19‐T cells expressing the CXCR4 S338X variant maintain receptor stability and sustain ERK and AKT signaling, which supports T‐cell effector function, migration, and survival. Therefore, the enhanced anti‐leukemic activity is conferred by CXCR4 S338X expression in CAR‐
Yushu Mao, Xiaodan Wang, Chun‐Hui Jin, Zhifeng Wei, Qinghao Ding, Ke‐Ke Zhang, Bo‐Wen Dong, Kai‐Wen Zheng, Yufei Hou, Tao Zhang, Wen‐Jie Zhao, Zheng Hu, Yong‐Guang Yang   +12 more
wiley   +1 more source

Prolonged Hematogone Expansion Is Associated with Better Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. [PDF]

Hematol Rep
Serio B, De Novellis D, Gorrese M, Bertolini A, Manzo P, Picone F, Della Corte AM, Marcucci R, Morini D, Rizzo M, Guariglia R, Luponio S, Scala P, Verdesca F, Sessa AM, Velino F, De Leucio M, Langella M, Giudice V, Selleri C.   +19 more
europepmc   +1 more source

Roles of TIF1β in Leukemic Stem Cell Through SETDB1‐Dependent and Independent Mechanisms

Cancer Science, EarlyView.
In leukemic stem cell, BCR::ABL cooperates with TIF1β to open chromatin at oncogenes and close chromatin at differentiation regulators, driving leukemic reprogramming. In TIF1β‐deficient stem cell, the loss of TIF1β inverts this balance, showing closed chromatin at oncogenes and open chromatin at differentiation regulators.
Mariko Morii, Sho Kubota, Goro Sashida
wiley   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation as a Platform to Treat Chemorefractory Acute Myeloid Leukemia in Adult Patients. [PDF]

Cancers (Basel)
Alzetta D, Cavattoni IM, Mosna F.
europepmc   +1 more source

Allogeneic Hematopoietic Stem Cell Transplant Recipient [PDF]

, 2020
openaire   +1 more source

Ethical and Regulatory Considerations in the Clinical Translation of Pluripotent Stem Cell‐Derived NK Cell Therapies

Cell Proliferation, EarlyView.
Advancements in the generation of human pluripotent stem cell‐derived natural killer (PSC‐NK) cells have attracted considerable attention within the biomedical research community, offering a promising off‐the‐shelf technique for universal immune therapy.
Qianwen Chen, Jianwei Lv, Xinwei Xie, Hanlin Zhu, Zhenyu Xiao, Yaojin Peng   +5 more
wiley   +1 more source

Recommendations for (Pharmaco)Genetic Sampling in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation. [PDF]

Clin Transl Sci
Bokma A, Matic M, Ralf A, van den Bosch BJC, Kayser M, van Schaik RHN, Lafeber M, Coenen MJH, Atrafi F.   +8 more
europepmc   +1 more source

Case report: Donor lymphocyte infusion and blinatumomab as treatment for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation [PDF]

Flavia Antonucci, Serena Marotta, Maria Celentano, Mariangela Pedata, Cira Riccardi, Cristina Luise, Angela Carobene, Simona Maria Muggianu, Assunta Viola, Mafalda Caputo, Stefania Leone, Ilaria Migliaccio, Barbara Pocali, Mirella Alberti, Claudio Falco, Mario Toriello, Felicetto Ferrara, Alessandra Picardi   +17 more
openalex   +1 more source

Application Strategies of Bone Marrow Mesenchymal Stromal Cells in Bone‐Related Diseases

Cell Proliferation, EarlyView.
Engineered BMSCs and vesicles enhance therapy effects for bone diseases via multi‐strategic approaches. ABSTRACT Bone‐related diseases (e.g., osteoporosis, osteoarthritis and fractures) exhibit a rising global incidence, imposing significant burdens on both quality of life and healthcare systems.
Xuemei Long, Dan Tan, Qianke Tao, Qiaonan Ye, Luwen Ye, Qing Li, Jingang Xiao   +6 more
wiley   +1 more source

Hospital at Home Following Allogeneic Hematopoietic Stem Cell Transplantation: An Economic Analysis. [PDF]

Healthcare (Basel)
Mishra V, Gedde-Dahl T, Remberger M, Solvang G, Selvaag KL, Fosseng A, Abrahamsen IW, Myhre AE, Hagen TP, Tjønnfjord GE.   +9 more
europepmc   +1 more source